Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

Kirsten Fischer, Othman Al‐Sawaf, Jasmin Bahlo, +29

New England Journal of Medicine

Lung adenocarcinoma promotion by air pollutants

William Hill, Emilia L. Lim, Clare E. Weeden, +320

Nature

AsthmaLung DepositionEnvironmental Lung DiseasesLung InflammationRespiratory Toxicology +6

Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial

Othman Al‐Sawaf, Can Zhang, Maneesh Tandon, +23

The Lancet Oncology

Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineImmunology +12

Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA

Christopher Abbosh, Alexander M. Frankell, Thomas Harrison, +300

Nature

EngineeringOncologic ImagingCancer DetectionMedicinePathology +6

The evolution of lung cancer and impact of subclonal selection in TRACERx

Alexander M. Frankell, Michelle Dietzen, Maise Al Bakir, +281

Nature

Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

François-Xavier Lescure, Hitoshi Honda, Robert Fowler, +289

The Lancet Respiratory Medicine

RETRACTED ARTICLE: Antibodies against endogenous retroviruses promote lung cancer immunotherapy

Kevin W. Ng, Jesse Boumelha, Katey S.S. Enfield, +325

Nature

The evolution of non-small cell lung cancer metastases in TRACERx

Maise Al Bakir, Ariana Huebner, Carlos Martínez‐Ruiz, +280

Nature

Genomic–transcriptomic evolution in lung cancer and metastasis

Carlos Martínez‐Ruiz, James R. Black, Clare Puttick, +291

Nature

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

Othman Al‐Sawaf, Can Zhang, Tong Lu, +19

Journal of Clinical Oncology